Worth Venture Partners’s Processa Pharmaceuticals PCSA Stock Holding History

Worth Venture Partners’s Portfolio PCSA Stock Details PCSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-142	Closed	-$78K	–	211
2022 Q4	$78K	Hold	142	–	–	0.05%	130
2022 Q3	$160K	Hold	142	–	–	0.1%	121
2022 Q2	$251K	Hold	142	–	–	0.15%	104
2022 Q1	$214K	Hold	142	–	–	0.1%	113
2021 Q4	$348K	Sell	142 -40	-22%	-$124K	0.17%	92
2021 Q3	$780K	Hold	182	–	–	0.35%	76
2021 Q2	$745K	Hold	182	–	–	0.28%	77
2021 Q1	$942K	Buy	+182	New	+$848K	0.46%	57

Other funds holding PCSA

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CBA

Coastal Bridge Advisors Westport, Connecticut $1.41B AUM 24.15% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Worth Venture Partners's PCSA Position: Q1 2023 in Review

Worth Venture Partners sold out of Processa Pharmaceuticals (PCSA) in Q1 2023, closing a stake of 142 shares — an estimated $78K sold.

Worth Venture Partners first reported a position in PCSA in Q1 2021 and held it in 8 quarters. The position peaked at $942K in Q1 2021. 22 funds tracked by Wall St. Rank hold PCSA as of Q1 2023.

Worth Venture Partners reported no remaining Processa Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Worth Venture Partners sold 142 Processa Pharmaceuticals shares in Q1 2023, an estimated $78K.
Worth Venture Partners first reported a position in Processa Pharmaceuticals in Q1 2021 and held it in 8 quarters.
Worth Venture Partners's Processa Pharmaceuticals position peaked at $942K in Q1 2021.
22 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q1 2023.

Based on Worth Venture Partners's 13F filing for Q1 2023, filed 15 May 2023.